U.S. Government Exercises Option to Purchase Additional RAPIVAB® (peramivir injection) from BioCryst for Pandemic Influenza Preparedness
The RAPIVAB purchase by the HHS Administration for Strategic Preparedness and Response will strengthen the nations preparedness to respond to a potential pandemic influenza event.
- The RAPIVAB purchase by the HHS Administration for Strategic Preparedness and Response will strengthen the nations preparedness to respond to a potential pandemic influenza event.
- Efficacy of RAPIVAB is based on clinical trials of naturally occurring influenza in which the predominant influenza infections were influenza A virus and a limited number of patients infected with influenza B virus.
- RAPIVAB is indicated for the treatment of acute uncomplicated influenza in patients 6 months and older who have been symptomatic for no more than 2 days.
- Prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use RAPIVAB.